Carolin M. Lieber

670 total citations
15 papers, 339 citations indexed

About

Carolin M. Lieber is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Carolin M. Lieber has authored 15 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Epidemiology and 2 papers in Molecular Biology. Recurrent topics in Carolin M. Lieber's work include Respiratory viral infections research (8 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Viral gastroenteritis research and epidemiology (4 papers). Carolin M. Lieber is often cited by papers focused on Respiratory viral infections research (8 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Viral gastroenteritis research and epidemiology (4 papers). Carolin M. Lieber collaborates with scholars based in United States, Netherlands and Slovakia. Carolin M. Lieber's co-authors include Richard K. Plemper, Robert M. Cox, Julien Sourimant, Josef D. Wolf, Michael G. Natchus, George R. Painter, Zachary M. Sticher, Chengjin Ye, Luis Martínez‐Sobrido and Alexander A. Kolykhalov and has published in prestigious journals such as Science, Nature Communications and Journal of Virology.

In The Last Decade

Carolin M. Lieber

13 papers receiving 335 citations

Peers

Countries citing papers authored by Carolin M. Lieber

Since Specialization

Citations

This map shows the geographic impact of Carolin M. Lieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolin M. Lieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolin M. Lieber more than expected).

Fields of papers citing papers by Carolin M. Lieber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolin M. Lieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolin M. Lieber. The network helps show where Carolin M. Lieber may publish in the future.

Co-authorship network of co-authors of Carolin M. Lieber

This figure shows the co-authorship network connecting the top 25 collaborators of Carolin M. Lieber. A scholar is included among the top collaborators of Carolin M. Lieber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolin M. Lieber. Carolin M. Lieber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Segmented filamentous bacteria reprogramming of alveolar macrophages limits postinfluenza bacterial pneumonia 2026 ·Science Immunology ·(unknown), Carolin M. Lieber, Hirohito Abo, Michal Kuczma, (unknown), Richard K. Plemper, Andrew T. Gewirtz	0
2	H5N1 Clade 2.3.4.4b: Evolution, Global Spread, and Host Range Expansion 2025 ·Pathogens ·Klaudia Chrząstek, Carolin M. Lieber, Richard K. Plemper	0
3	Influenza A virus resistance to 4’-fluorouridine coincides with viral attenuation in vitro and in vivo 2024 ·PLoS Pathogens ·Carolin M. Lieber, (unknown), Megha Aggarwal, Nicole A. P. Lieberman, (unknown), Jeong-Joong Yoon, Michael G. Natchus, Robert M. Cox, Alexander L. Greninger, Richard K. Plemper	4
4	Intestinal microbiota programming of alveolar macrophages influences severity of respiratory viral infection 2024 ·Cell Host & Microbe ·Vu L. Ngo, Carolin M. Lieber, (unknown), Kaori Sakamoto, Michal Kuczma, Richard K. Plemper, Andrew T. Gewirtz	34
5	Therapeutic mitigation of measles-like immune amnesia and exacerbated disease after prior respiratory virus infections in ferrets 2024 ·Nature Communications ·Robert M. Cox, Josef D. Wolf, Nicole A. P. Lieberman, Carolin M. Lieber, (unknown), Zachary M. Sticher, Jeong-Joong Yoon, (unknown), (unknown), (unknown), (unknown), Michael G. Natchus, Andrew T. Gewirtz, Rik L. de Swart, Alexander A. Kolykhalov, Khan Hekmatyar, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper	5
6	Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection 2024 ·Journal of Virology ·Carolin M. Lieber, (unknown), (unknown), Zachary M. Sticher, Vu L. Ngo, Andrew T. Gewirtz, Alexander A. Kolykhalov, Michael G. Natchus, Alexander L. Greninger, Mehul S. Suthar, Richard K. Plemper	3
7	Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets 2024 ·iScience ·(unknown), (unknown), (unknown), (unknown), V. Poikalainen, (unknown), (unknown), (unknown), Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, Richard K. Plemper, Andres Männik, Mart Ustav, Joachim M. Gerhold	1
8	Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models 2023 ·Nature Communications ·Robert M. Cox, Carolin M. Lieber, Josef D. Wolf, Amir-Hossein Karimi, Nicole A. P. Lieberman, Zachary M. Sticher, Pavitra Roychoudhury, (unknown), (unknown), Michael G. Natchus, George R. Painter, Alexander A. Kolykhalov, Alexander L. Greninger, Richard K. Plemper	18
9	4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses 2023 ·PLoS Pathogens ·Carolin M. Lieber, Megha Aggarwal, Jeong-Joong Yoon, Robert M. Cox, (unknown), Julien Sourimant, Märt Toots, Scott K. Johnson, Cheryl A. Jones, Zachary M. Sticher, Alexander A. Kolykhalov, Manohar Saindane, S. Mark Tompkins, Oliver Planz, George R. Painter, Michael G. Natchus, Kaori Sakamoto, Richard K. Plemper	20
10	4′-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness 2022 ·DNA and Cell Biology ·Carolin M. Lieber, Richard K. Plemper	8
11	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model 2022 ·Nature Communications ·Carolin M. Lieber, Robert M. Cox, Julien Sourimant, Josef D. Wolf, (unknown), Quynh Phung, Manohar Saindane, (unknown), Zachary M. Sticher, (unknown), Michael G. Natchus, George R. Painter, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper	33
12	4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication 2022 ·Science ·Julien Sourimant, Carolin M. Lieber, Megha Aggarwal, Robert M. Cox, Josef D. Wolf, Jeong-Joong Yoon, Märt Toots, Chengjin Ye, Zachary M. Sticher, Alexander A. Kolykhalov, Luis Martínez‐Sobrido, Gregory R. Bluemling, Michael G. Natchus, George R. Painter, Richard K. Plemper	79
13	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. 2022 ·PubMed ·Julien Sourimant, Carolin M. Lieber, Megha Aggarwal, Robert M. Cox, Josef D. Wolf, Jeong-Joong Yoon, Märt Toots, Chengjin Ye, Zachary M. Sticher, Alexander A. Kolykhalov, Luis Martínez‐Sobrido, Gregory R. Bluemling, Michael G. Natchus, George R. Painter, Richard K. Plemper	45
14	Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase 2022 ·Science Advances ·Julien Sourimant, Carolin M. Lieber, Jeong-Joong Yoon, Märt Toots, (unknown), (unknown), Kaori Sakamoto, Michael G. Natchus, Joseph M. Patti, John Vernachio, Richard K. Plemper	16
15	Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets 2021 ·Nature Communications ·Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, Julien Sourimant, Michelle J. Lin, Darius Babusis, (unknown), (unknown), (unknown), Diane S. Lye, Rao Kalla, Kwon Soo Chun, Richard L. Mackman, Chengjin Ye, Tomáš Cihlář, Luis Martínez‐Sobrido, Alexander L. Greninger, John P. Bilello, Richard K. Plemper	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact